13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
40 檔
50.4%
As reported in its official Q4 2024 Form 13F filing, Vivo Capital, LLC's tracked investment portfolio stood at $1.1B with 40 total positions.
In Q4 2024, Vivo Capital, LLC adopted a defensive or profit-taking posture, trimming 3 positions and completely liquidating 7 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, VRNA, GERN) accounted for 50.4% of total reported equity market value during Q4 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 31.68% | -0.82% | EXIT | |
| 2 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 11.88% | — | -35.66% | |
| 3 | GERN | Geron CORP | Stock-Other | 10.80% | -0.06% | — | |
| 4 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 4.28% | -5.85% | EXIT | |
| 5 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.16% | — | — | |
| 6 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.94% | +0.81% | — | |
| 7 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 2.47% | +1.15% | — | |
| 8 | DCTH | Delcath Systems Inc | Stock-Other | 2.30% | — | +71.37% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.11% | -0.27% | EXIT | |
| 10 | CDTX | Cidara Therapeutics Inc | Stock-Other | 2.02% | — | — | |
| 11 | ERAS | Erasca Inc | Stock-Other | 1.90% | -9.44% | — | |
| 12 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.61% | +3.63% | +116.25% | |
| 13 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.56% | — | — | |
| 14 | RZLT | Rezolute Inc | Stock-Other | 1.54% | — | — | |
| 15 | SERA | Sera Prognostics Inc-a | Stock-Other | 1.51% | -0.01% | — | |
| 16 | TRML | Tourmaline Bio Inc | Stock-Other | 1.34% | — | — | |
| 17 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 1.34% | +0.42% | +49.24% | |
| 18 | TIL | Instil Bio Inc | Stock-Other | 1.25% | +0.01% | -6.22% | |
| 19 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.16% | -0.12% | — | |
| 20 | ABEO | Abeona Therapeutics Inc | Stock-Other | 1.15% | — | — | |
| 21 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.09% | — | — | |
| 22 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.02% | +0.19% | — | |
| 23 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 0.98% | -0.06% | — | |
| 24 | COGT | Cogent Biosciences Inc | Stock-Other | 0.98% | -1.35% | EXIT | |
| 25 | CELC | Celcuity Inc | Stock-Other | 0.90% | — | — | |
| 26 | VSTM | Verastem Inc | Stock-Other | 0.89% | — | — | |
| 27 | ✓ | Stock-Other | 0.89% | — | +123.04% | ||
| 28 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 29 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 0.85% | — | — | |
| 30 | CMPS | Compass Pathways PLC | Stock-Other | 0.68% | -0.09% | EXIT | |
| 31 | IOBTQ | Io Biotech Inc | Stock-Other | 0.64% | — | — | |
| 32 | ALGS | Aligos Therapeutics Inc | Stock-Other | 0.63% | — | — | |
| 33 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.58% | -2.65% | — | |
| 34 | ALLKGUSD | Allakos Inc | Stock-Other | 0.40% | — | — | |
| 35 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.22% | — | — | |
| 36 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.21% | — | — | |
| 37 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.14% | +3.04% | — | |
| 38 | DBVT | Dbv Technologies Sa-spon Adr | Stock-Other | 0.01% | -1.87% | — | |
| 39 | QTTB | Q32 Bio Inc | Stock-Other | 0.01% | — | — | |
| 40 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | +5.4% | — | Unchanged |
| 2 | VRNA | Verona Pharma PLC - Adr | +3.4% | -35.66% | Trim |
| 3 | ACRS | Aclaris Therapeutics Inc | +2.5% | NEW | New buy |
| 4 | CDTX | Cidara Therapeutics Inc | +2% | NEW | New buy |
| 5 | DCTH | Delcath Systems Inc | +1.6% | +71.37% | Add |
| 6 | TRVI | Trevi Therapeutics Inc | +1.2% | +116.25% | Add |
| 7 | DRUG | Bright Minds Biosciences Inc | +1% | NEW | New buy |
| 8 | ✓ | +0.7% | +123.04% | Add | |
| 9 | CRVS | Corvus Pharmaceuticals Inc | +0.7% | +49.24% | Add |
| 10 | GERN | Geron CORP | +0.6% | — | Unchanged |
| 11 | ALGS | Aligos Therapeutics Inc | +0.5% | — | Unchanged |
| 12 | VSTM | Verastem Inc | +0.5% | — | Unchanged |
| 13 | SERA | Sera Prognostics Inc-a | +0.4% | — | Unchanged |
| 14 | RZLT | Rezolute Inc | +0.4% | — | Unchanged |
| 15 | ERAS | Erasca Inc | +0.4% | — | Unchanged |
| 16 | ✓ | Avadel Pharmaceuticals PLC ADR | +0.3% | — | Unchanged |
| 17 | ALLKGUSD | Allakos Inc | +0.2% | — | Unchanged |
| 18 | RGLS | Regulus Therapeutics Inc | +0.2% | — | Unchanged |
| 19 | ABEO | Abeona Therapeutics Inc | +0.2% | — | Unchanged |
| 20 | CATBUSD | Astria Therapeutics Inc | +0.2% | — | Unchanged |
| 21 | CELC | Celcuity Inc | +0.2% | — | Unchanged |
| 22 | IOBTQ | Io Biotech Inc | +0.1% | — | Unchanged |
| 23 | TRML | Tourmaline Bio Inc | +0.1% | — | Unchanged |
| 24 | ORIC | Oric Pharmaceuticals Inc | +0.1% | — | Unchanged |
| 25 | TENX | Tenax Therapeutics Inc | +0.1% | — | Unchanged |
| 26 | CMPX | Compass Therapeutics Inc | 0% | — | Unchanged |
| 27 | BOLT1EUR | Bolt Biotherapeutics Inc | 0% | — | Unchanged |
| 28 | DBVT | Dbv Technologies Sa-spon Adr | 0% | NEW | New buy |
| 29 | DTIL | Precision Biosciences Inc | — | — | Unchanged |
| 30 | COGT | Cogent Biosciences Inc | 0% | — | Unchanged |
| 31 | CRBP | Corbus Pharmaceuticals Holdi | -0.1% | — | Unchanged |
| 32 | QTTB | Q32 Bio Inc | -0.1% | — | Unchanged |
| 33 | ✓ | Dbv Technologies S A | -0.1% | EXIT | Sold out |
| 34 | CDXS | Codexis Inc | -0.1% | EXIT | Sold out |
| 35 | CMPS | Compass Pathways PLC | -0.2% | — | Unchanged |
| 36 | DYN | Dyne Therapeutics Inc | -0.4% | — | Unchanged |
| 37 | ✓ | Engene Holdings Inc | -0.4% | EXIT | Sold out |
| 38 | 430 | Terns Pharmaceuticals Inc | -0.5% | — | Unchanged |
| 39 | AVU0 | Adverum Biotechnologies Inc | -0.5% | EXIT | Sold out |
| 40 | OLMA | Olema Pharmaceuticals Inc | -0.5% | — | Unchanged |
| 41 | ZBIO | Zenas Biopharma Inc | -0.6% | — | Unchanged |
| 42 | ALXO | Alx Oncology Holdings Inc | -0.6% | EXIT | Sold out |
| 43 | SLN | Silence Therapeutics Plc-adr | -0.8% | — | Unchanged |
| 44 | VRDN | Viridian Therapeutics Inc | -1.1% | -41.45% | Trim |
| 45 | TIL | Instil Bio Inc | -2.2% | -6.22% | Trim |
| 46 | SVA | Sinovac Biotech Ltd. | -6.3% | EXIT | Sold out |
| 47 | HRMY | Harmony Biosciences Holdings | -8.6% | EXIT | Sold out |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 40 disclosed positions in Q4 2024.
During Q4 2024, Vivo Capital, LLC's top holdings by market value included SLNOEUR (31.7%)、VRNA (11.9%)、GERN (10.8%). The largest single position, SLNOEUR, represented 31.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ACRS
市值: $22.0M
Top Position Liquidated / Trimmed
HRMY
前期市值: $104.2M
In Q4 2024, Vivo Capital, LLC made 18 total portfolio adjustments, initiating 4 new buys, adding to 4 positions, trimming 3 holdings, and fully liquidating 7 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.